Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT6008 in Advanced Pancreatic Cancer
NCT06278454Phase 1Recruiting
- Sponsor
- Chengdu Newray Medical Technology
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NRT6008 in pancreatic cancer (PC), sponsored by Chengdu Newray Medical Technology. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose-Limiting Toxicity at 28 days and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
NRT6008
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06278454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278454.